Log In
Print
BCIQ
Print
Print this Print this
 

Cipro, ciprofloxacin, Inhaled ciprofloxacin (BAY Q3939)

  Manage Alerts
Collapse Summary General Information
Company Bayer AG
DescriptionInhaled formulation of 4-quinolone (ciprofloxacin)
Molecular Target DNA gyrase
Mechanism of ActionProkaryotic replication inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationPseudomonas
Indication DetailsTreat chronic lung infection due to Pseudomonas aeruginosa in cystic fibrosis (CF) patients
Regulatory Designation

U.S. - Orphan Drug (Treat chronic lung infection due to Pseudomonas aeruginosa in cystic fibrosis (CF) patients);
EU - Orphan Drug (Treat chronic lung infection due to Pseudomonas aeruginosa in cystic fibrosis (CF) patients)

Partner

Nektar Therapeutics


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today